cancer next generation sequencing clinical implementation in clia/cap facility
DESCRIPTION
Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility. Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMG Associate Professor of Pediatrics, Genetics, Pathology and Immunology Medical Director of Genomics and Pathology Services. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/1.jpg)
Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility
Shashikant Kulkarni, M.S (Medicine)., Ph.D., FACMGAssociate Professor of Pediatrics, Genetics, Pathology and Immunology
Medical Director of Genomics and Pathology Services
![Page 2: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/2.jpg)
Why do we need NGS for clinical cancer diagnostics?
![Page 3: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/3.jpg)
Advantages of detecting mutations with next-generation sequencing
High throughput Test many genes at once
Systematic, unbiased mutation detection All mutation types
▪ Single nucleotide variants (SNV), copy number alteration (CNA)-insertions, deletions and translocations
Digital readout of mutation frequency Easier to detect and quantify mutations in a
heterogeneous sample Cost effective precision medicine
“Right drug at right dose to the right patient at the right time”
![Page 4: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/4.jpg)
Unique challenges for implementing NGS for clinical cancer diagnostics
![Page 5: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/5.jpg)
Complexity of Cancer genomes
Cancer genomes are extremely complex and diverse Mutation frequency
▪ Degree of variation in cancer cells compared to reference genome
Copy number/ploidy▪ Most tumors are aneuploid▪ Bioinformatic software assume diploid status
Genome structure
![Page 6: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/6.jpg)
Cancer-specific challenges Genomic alterations in cancer found at low-
frequency Samples vary in quantity, quality and purity from
constitutional samples Quantity
▪ Limiting for biopsy specimens▪ Whole genome amplification not ideal
Quality▪ Most biopsies are formalin fixed, require special protocols ▪ Often include necrotic, apoptotic cells
Purity (tumor heterogeneity)▪ Admixture with normal cells (need pathologists to ensure test
is performed on DNA from tumor cell)▪ Within cancer heterogeneity (different clones)
![Page 7: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/7.jpg)
Sample procurement and pre-analytical issues
FFPE (formalin-fixed, paraffin-embedded) samples Age, temperature, processing
Fresh tissues Not ideal without accompanying pathology
investigation and marking of tumor cell population to guard against dilution effect on total DNA extracted
Fine needle biopsies Very few cells available NGS methods will need to work by decreasing
minimum inputs of DNA
![Page 8: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/8.jpg)
Implementation of NGS for clinical cancer diagnostics
![Page 9: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/9.jpg)
Clinical Next Generation Sequencing in Cancer Goals
High throughput, cost effective multiplexed sequencing assay with deep coverage
Target clinically actionable regions in clinically relevant time
Challenges Huge infrastructure costs Bioinformatic barriers
Solution Leverage expertise and resources across
Pathology, Bioinformatics and Genetics
![Page 10: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/10.jpg)
Example process of targeted sequencing panel in cancer
From “soup to nuts”
![Page 11: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/11.jpg)
Test overview
![Page 12: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/12.jpg)
Cancer Gene Panel
Genes DiseaseALK Lymphoma, LungBRAF Brain, Colon, Lung, Melanoma, Thyroid
CEBPA AMLCTNNB1 Colon, Desmoid Tumor, Liver, Lung, Prostate, Renal, ThyroidCHIC2 Myeloid Neoplasms w/EosinophiliaCSF1R AML, GISTDNMT3A AMLEGFR Colon, LungFLT3 AMLIDH1 AML, BrainIDH2 AML, BrainJAK2 Myeloproliferative NeoplasmsKIT AML, GIST, Systemic MastocytosisKRAS Colon, Endometrium, Lung, Melanoma, Pancreatic, ThyroidMAPK1(ERK) Lung, MelanomaMAPK2(MEK) Lung, MelanomaMET Lung, MelanomaMLL AMLNPM1 AMLNRAS Colon, Lung, Melanoma, Pancreatic, ThyroidPDGFRA GIST, SarcomaPIK3CA Colon, Lung, Melanoma, PancreaticPTEN Brain, Endometrium, Melanoma, Ovarian, Prostate, TestisPTPN11 JMML, MDSRET MEN2A/2B (adrenal), ThyroidRUNX1 AMLTP53 Colon, Lung, PancreaticWT1 AML, Renal, Wilms Tumor
![Page 13: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/13.jpg)
Target definitions
Exons +/- 200 bp, plus 1000 bp +/- each gene
AUG STOPTSS poly(A)
promoter
splice signals
![Page 14: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/14.jpg)
Getting started
Capture efficiency and coverage Overall and by gene
Specimen type differences Fresh-frozen vs. FFPE specimens
Detection of single nucleotide variants (SNVs) Methods Filters
Detection of indels and other mutation types Methods
![Page 15: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/15.jpg)
First steps
HapMap samplesKnown genotypes
lung adenocarcinomasKnown genotypes
frozen DNA sample+
FFPE DNA sample
Library prep, target enrichment
Multiplex sequencing
Analysis (coverage and comparison with genotypes)
![Page 16: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/16.jpg)
Significant variation in coverage by geneC
over
age
Capture baits
Target region
1000x
500 bp
Cov
erag
e
1000x
Capture baits
Target region
500 bp
Good coverage of EGFR Poor coverage of CEBPA
![Page 17: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/17.jpg)
Significant variation in coverage by gene
NA19129 coverage distribution by gene (black bar = median; box = 25-75%ile)
* *
Capture for genes with poor coverage have been redesigned
![Page 18: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/18.jpg)
Fresh vs. FFPE: Coverage by gene
Tumor 1 normalized coverage, by gene(solid = frozen, hatched = FFPE)
Only minor differences are apparent between fresh-frozen and FFPE data
![Page 19: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/19.jpg)
Re-designing of capture set
![Page 20: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/20.jpg)
Defining clinical NGS guidelines
![Page 21: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/21.jpg)
http://www.cdc.gov/genomics/gtesting/ACCE/
ACCE
![Page 22: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/22.jpg)
Defining clinical validation
AccuracyDegree of agreement between the nucleic acid sequences derived from the assay and a reference sequence
Precision
Repeatability—degree to which the same sequence is derived in sequencing multiple reference samples, many times. Reproducibility—degree to which the same sequence is derived when sequencing is performed by multiple operators and by more than one instrument.
Analytical Sensitivity
The likelihood that the assay will detect a sequence variation, if present, in the targeted genomic region.
Analytical Specificity
The probability that the assay will not detect a sequence variation, if none are present, in the targeted genomic region.
Diagnostic Specificity
The probability that the assay will not detect a clinically relevant sequence variation, if none are present, in the targeted genomic region.
![Page 23: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/23.jpg)
Reproducibility
Test Type Definitions
Inter-Tech (Stringent)
The technicians performing the run were different, but the experiment and lanes were the same.
Inter-Tech (Relaxed) The technicians performing the run were different for each comparison. We did not control for the experiment or lane.
Intra-Tech The technician performing the run was the same. The experiment was different.
Inter-Lane (All) The lanes are different. These experiments, the techs were different in two, and the same in two.
Inter-Lane & Intra-Tech
The lanes are different. In these experiments, the techs were the same.
Intra-Lane & Inter-Tech
The lanes are the same. In these experiments, the techs were different.
![Page 24: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/24.jpg)
Reproducibility
Inter-Tech (Stringent)
Inter-Tech (Relaxed)
Intra-Tech Inter-Lane (All)
Inter-Lane & Intra-Tech
Intra-Lane & Inter-Tech
90.0%
92.0%
94.0%
96.0%
98.0%
100.0%
98.1% 97.9%97.1%
98.6% 98.7% 98.4%
Reproducibility
Variability Method
Perc
ent A
gree
men
t
![Page 25: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/25.jpg)
Major barriers for clinical implementation of NGS
![Page 26: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/26.jpg)
Data tsunami
![Page 27: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/27.jpg)
1. Need expertise in Biomedical Informatics
2. Need clinical grade “user-friendly-soup to nuts” software solution
![Page 28: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/28.jpg)
3. Hardware
![Page 29: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/29.jpg)
Informatics pipeline workflow
Patient Physician
Sample
OrderSequence
Tier 1:Base CallingAlignment
Variant Calling
Tier 2:Genome Annotation
Medical Knowledgebase
Tier 3: Clinical Report
EHR
![Page 30: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/30.jpg)
Order Intake
• Patient samples accessioned in Cerner CoPath• Gene panels ordered through CoPath• Orders received will initiate workflow
HL7
![Page 31: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/31.jpg)
Order Intake
![Page 32: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/32.jpg)
Tier 1 Informatics
• Optimized pipelines using several base callers, aligners, and variant calling algorithms to meet CAP/CLIA standards– Easily customizable and updateable
• Facilitates new panel introduction and the rapid delivery of novel analytical tools and pipelines
– Seamless to the clinical genomicist
![Page 33: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/33.jpg)
Inspection of coverage for each run
![Page 34: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/34.jpg)
QC metrics (sample level)
![Page 35: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/35.jpg)
QC metrics (exon level)
![Page 36: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/36.jpg)
Tier 1 Informatics
![Page 37: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/37.jpg)
Cancer specific analysis pipeline
Data Output
FASTQ Sequence
Output
HiSeqMiSeq
NovoalignTM
SNVCalls
IndelCalls
TranslocationValidation
GATK/Samtools
Pindel
Breakdancer SLOPE
Parse Data
SNVFiltering
MergedVCF file
TranslocationCalls
Read Alignment
![Page 38: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/38.jpg)
Tier 2 Informatics
• Deliver a clinical grade variant database that meets CAP/CLIA standards– Requires combined expertise of
informaticians and clinical genomocists/pathologists
• Future interoperability with (inter)national variant databases that meet CAP/CLIA standards
![Page 39: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/39.jpg)
Tier 2 Informatics
![Page 40: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/40.jpg)
Tier 3 Informatics
EGFR (L858R)
Response rates of >70% in patients with non-small cell lung cancer treated with either erlotinib or gefitinib
KRAS (G12C)
Poor response rate in patients with non-small cell lung cancer treated with either erlotinib or gefitinib
+
![Page 41: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/41.jpg)
Tier 3 Informatics: Variant classificaiton
![Page 42: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/42.jpg)
Clinical NGS process map
![Page 43: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/43.jpg)
Conclusions• Cancer NGS gene panel helps in
multiplexing key actionable genes for a cost effective, accurate and sensitive assay
• Targeted cancer panel are useful for “drug repurposing” of small molecule inhibitors
• Clinical validation of NGS assays in cancer is complex and labor intensive but basic principles remain
• Bioinformatic barriers are the most challenging
![Page 44: Cancer Next Generation Sequencing Clinical Implementation in CLIA/CAP facility](https://reader031.vdocuments.net/reader031/viewer/2022013004/568132b9550346895d99750b/html5/thumbnails/44.jpg)
Karen Seibert, John Pfiefer, Skip Virgin, Jeffrey Millbrandt, Rob Mitra, Rich HeadRakesh Nagarajan and his Bioinf. teamDavid Spencer, Eric Duncavage, Andy Bredm.Hussam Al-Kateb, Cathy CottrellDorie Sher, Jennifer StratmanTina Lockwood, Jackie PaytonMark Watson, Seth Crosby, Don ConradAndy Drury, Kris Rickoff, Karen NovakMike Isaacs and his IT TeamNorma Brown, Cherie Moore, Bob FeltmannHeather Day, Chad Storer, George BijoyDayna Oschwald, Magie O Guin, GTAC teamJane Bauer and Cytogenomics &Mol path team
MANY MORE!